Astellas Pharma Inc. (ALPMF)

11.82 0.00 (0.00%) At close: 04:00PM EDT

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 14,754

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Naoki Okamura BSc	President, CEO & Director	1.96M	N/A	1962
Mr. Atsushi Kitamura	Senior Executive Officer & CFO	N/A	N/A	N/A
Nobue Yasuda	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Mr. Yoshitsugu Shitaka Ph.D.	Chief Scientific Officer & Senior Managing Executive Officer	N/A	N/A	N/A
Ms. Catherine B. Levitt	General Counsel	N/A	N/A	N/A
Mr. Katsuyoshi Sugita	Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director	N/A	N/A	1967
Mr. Stig Ogata	Vice President of Corporate Communications	N/A	N/A	N/A
Ms. Tatjana Dragovic	Senior VP and Head of Ethics & Compliance	N/A	N/A	N/A
Mr. Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	N/A	N/A	N/A
Jun Kono	Senior Executive Officer & Head of Japan Commercial	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate governance

Astellas Pharma Inc.’s ISS governance QualityScore as of 1 October 2024 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.